Skip to main content
Explore URMC


Kidney Cancer: A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Research Question:
What are the good or bad effects of atezolizumab versus placebo on you and your Renal Cell Carcinoma (RCC)?

Basic Study Information

You will be randomly assigned to one of the following treatment groups: atezolizumab or placebo. Neither you nor your study doctor may choose the group you will be in. You will have a 50/50 chance of being placed in either group.

Location: Cancer Center
Study Web URL:
Study Reference #: IGUK17001

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Guancial

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Renal Cell

More information about Kidney Cancer

Return to Search